Nicholas Piramal India Ltd. (NPIL) is among the largest pharmaceuticals companies with an inimitable mix of inorganic and organic growth. It has supreme record of managing JV’s/ Alliances/ partnership. NPIL had a net sales turnover of US $313 million in 2005-06.
NPIL was established in 1988, when Piramal group acquired a small formulation company named Nicholas Laboratories from Sara Lee. It has joint ventures and alliances with some of the finest global names in the industry, including Allergan Inc., USA; UK; F. Hoffmann-La Roche Ltd., Switzerland; Gilead Sciences, USA; Cheissi, Italy; and IVAX Corp; UK.
The company products have a wide range and include nine key therapeutic areas such as Neuro-psychiatry, Cardio-vascular, Diabetes Management, Respiratory, Anti-infectives, Oncology, Gastro-intestinals, NSAIDS and Dermatology.
Nicholas is the leader in the cardio-vascular segment and has a strong market share in Anti- Diabetics Segment, Antibiotics & Respiratory Segments, Neuro-psychiatry and Pain Management.
Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint are the biggest brands of the company and they bring about 67% of the Revenue. Other secondary brands such as Paraxin, Flagyl and Omnatax contribute to around 24% of the Revenues.
In India it has around 2700 robust field personnel. NPIL has recently acquired Pfizer’s Morepeth’s manufacturing unit in UK and become one of the leading custom manufacturing organizations across the world.
Nicholas Piramal India Limited
Nicholas Piramal Tower
Ganpatrao Kadam Marg
Lower Parel, Mumbai 400 013
Quarterly Results of Nicholas Piramal
|Dec 2006(3 rd quarter)||Sept 2006(2nd quarter)||Dec 2005(3 rd quarter)|
|% Change (Over Sep 2006)||% Change (Over Dec 2005)|
Annual results of Nicholas Piramal
|(12 Months)||(12 Months)||% Changes|